Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

PHASE2TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 15, 2007

Primary Completion Date

April 4, 2012

Study Completion Date

April 4, 2012

Conditions
Cushing's Syndrome
Interventions
DRUG

Mifepristone

Singe dose

Trial Locations (15)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

CHU de Bordeaux Hopital Haut Leveque, Bordeaux

C.H.U Albert Michallon, Grenoble

C.H.U. de Bicetre, Le Kremlin-Bicêtre

CHRU de Lille, Lille

Hopital de la Timone, Marseille

AP-HP, Hopital Cochin Pavillon CORNIL, Paris

CHU de Toulouse, Toulouse

University of Wuerzburg, Wuerzbug

Universita Degli Studi, Napoli

University of Turin, Orbassano

University of Padova, Padua

Internal Medicine Endocrinology, Eindhoven

University Hosiptal of Groningen, Groningen

Erasmus Medical Center, Rotterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HRA Pharma

INDUSTRY

NCT00422201 - Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion | Biotech Hunter | Biotech Hunter